Lobbyists Say Chaffetz Probe Into EpiPen Price Is A Bad Sign For Rx Makers

The House Oversight & Government Reform Committee on Monday (Aug. 29) launched a bipartisan investigation into Mylan Pharmaceuticals' pricing of EpiPen, and some lobbyists believe this letter, more so than other letters from lawmakers on drug prices, indicates that the controversy over EpiPen price hikes isn't going away soon. Lawmakers might be reacting aggressively because it is election season, but some expect the EpiPen controversy to spill over into next year when Congress reauthorizes drug user fee legislation. It's common...